Avacta Group PLC Hardman report: New Affimer opportunities
July 19 2016 - 2:15AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
19 July 2016
Hardman report: New Affimer development opportunities
Hardman & Co research report: New Affimer development
opportunities
Avacta is a life science company providing high quality and
highly specific tools to the biopharmaceutical industry to help in
the diagnosis and treatment of humans and animals. The group's
Affimer technology is a revolutionary alternative to the
established antibody technology which dominates the drug industry
despite its limitations. While Avacta has made considerable
progress towards developing its own bio-therapeutics in 2016, two
announcements recently have expanded its Affimer technology into
new areas with large commercial potential. There remains a clear
mismatch between the current EV and the long-term potential of
Affimers.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/18-07-16-new-affimer-development-opportunities
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com
11/12 Tokenhouse Dr Gregoire Pave
Yard gp@hardmanandco.com
London Telephone: +44 20 7929 3399
EC2R 7AS Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMGMNVRGGVZM
(END) Dow Jones Newswires
July 19, 2016 02:15 ET (06:15 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024